Tr1X Announces FDA IND Approval for Off-the-Shelf Treg Therapy TRX103 Targeting Refractory Crohn’s Disease

Disclaimer: Due to limited proficiency, errors are inevitable, and some information may not be the latest. Feel free to point out in the comments. This article only introduces drugs related to medical health and does not recommend treatment plans (if involved); this article does not constitute any investment advice.

Recently,Cell Therapy Pioneer Tr1X Announces FDA Approval of IND for Cell Drug TRX103, a Treatment for RefractoryCrohn's DiseaseEngineered Tr1 Treg Cell Therapy,Tr1X plans to initiate a Phase 1/2a clinical trial and administer the first patient dose by the end of 2024.

Earlier this year, Tr1X announced the completion of a $75 million Series A financing round, emerging from stealth mode.Focus on developmentNovel AllogeneicRegulatory T cells (Treg) and CAR-Treg cell therapy introduce treatments that target and potentially cure autoimmune and inflammatory diseases.

The company's scientific research is mainly based on Tr1X.Founder of the discipline and medical doctor Maria Grazia Roncarolo’s research findings. She is the discoverer of Type 1 regulatory T cells (Tr1). Tr1 cells are a differentiated subset of regulatory T cells, crucial for maintaining balance and tolerance within a healthy human body, and possess various important functions. These functions include suppressing local inflammation and downregulating.Inflammasome, inhibit pathogenic effector T cell responses, and induce long-term tolerance,This has been observed in both preclinical models and patients.

Tr1X's proprietary technology can isolate CD4+ T cells from healthy donors.Cell TransformationFor Treg-like cells, these cells have functions and characteristics similar to natural Tr1 cells. These cells are further engineered to target specific tissues or organs, achieving localized targeted immune modulation. With proprietary GMP-gradeClosed-loop SystemTr1X can achieve scaled production of products and provide consistency, quality, and reliability.

Reference: Company official website